Publications from month 19 to 36 of the project:

1. Björkbacka H, Alm R, Persson M, Hedblad B, Nilsson J, Nordin Fredrikson G. Low levels of apoB-100 autoantibodies are associated with increased risk of coronary events. Arterioscler Thromb Vasc Biol, 36, 765-71, 2016.

2. Gisterå A, Hermansson A, Strodthoff D, Klement M, Hedin U, Fredrikson GN, Nilsson J, Hansson G, Ketelhuth D. Vaccination against T-cell epitopes of native ApoB100 reduces vascular inflammation and disease in a humanized mouse model of atherosclerosis. J Intern Med, in press.

3. Sage AP, Mallat Z. Readapting the adaptive immune response - therapeutic strategies for atherosclerosis. Br J Pharmacol. 2017 Jan 4. doi: 10.1111/bph.13700. [Epub ahead of print]

4. Tsiantoulas D, Bot I, Ozsvar-Kozma M, Göderle L, Perkmann T, Hartvigsen K, Conrad DH, Kuiper J, Mallat Z, Binder CJ. Increased Plasma IgE Accelerate Atherosclerosis in Secreted IgM Deficiency. Circ Res. 2017 Jan 6;120(1):78-84. doi: 10.1161/CIRCRESAHA.116.309606.

5. Steinmetz M, Ponnuswamy P, Laurans L, Esposito B, Tedgui A, Mallat Z. The intravenous injection of oxidized LDL- or Apolipoprotein B100--Coupled splenocytes promotes Th1 polarization in wildtype and Apolipoprotein E--Deficient mice. Biochem Biophys Res Commun. 2015 Aug 14;464(1):306-11

6. Gruber S, Hendrikx T, Tsiantoulas D, Ozsvar-Kozma M, Göderle L, Mallat Z, Witztum JL, Shiri-Sverdlov R, Nitschke L, Binder CJ.Sialic Acid-Binding Immunoglobulin-like Lectin G Promotes Atherosclerosis and Liver Inflammation by Suppressing the Protective Functions of B-1 Cells. Cell Rep. 2016 Mar 15;14(10):2348-61.

7. Douna H, Kuiper J. Novel B-cell subsets in atherosclerosis. Curr Opin Lipidol. 2016 Oct;27(5):493-8.

8. Schaftenaar F, Frodermann V, Kuiper J, Lutgens E. Atherosclerosis: the interplay between lipids and immune cells. Curr Opin Lipidol. 2016 Jun;27(3):209-15

 

Publications from months 1 to 18 of the project:

1: Ketelhuth DF, Hansson GK. Modulation of autoimmunity and atherosclerosis - common targets and promising translational approaches against disease. Circ J. 2015 Apr 24;79(5):924-33. doi:
10.1253/circj. CJ-15-0167. PMID: 25766275.

2: Polyzos KA, Ovchinnikova O, Berg M, Baumgartner R, Agardh H, Pirault J, Gisterå A, Assinger A, Laguna-Fernandez A, Bäck M, Hansson GK, Ketelhuth DF. Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoe-/- mice. Cardiovasc Res. 2015 May 1;106(2):295-302. doi:10.1093/cvr/cvv100. Epub 2015 Mar 5. PubMed PMID:25750192.

3: Johansson ME, Ulleryd MA, Bernardi A, Lundberg AM, Andersson A, Folkersen L, Fogelstrand L, Islander U, Yan ZQ, Hansson GK. α7 Nicotinic acetylcholine receptor is expressed in human atherosclerosis and inhibits disease in mice--brief report. Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2632-6.

4: Sage AP, Murphy D, Maffia P, Masters LM, Sabir SR, Baker LL, Cambrook H, Finigan AJ, Ait-Oufella H, Grassia G, Harrison JE, Ludewig B, Reith W, Hansson GK, Reizis B, Hugues S, Mallat Z.
MHC Class II-restricted antigen presentation by plasmacytoid dendritic cells drives proatherogenic T cell immunity. Circulation. 2014 Oct 14;130(16):1363-73.

5: Johansson ME, Zhang XY, Edfeldt K, Lundberg AM, Levin MC, Borén J, Li W, Yuan XM, Folkersen L, Eriksson P, Hedin U, Low H, Sviridov D, Rios FJ, Hansson GK, Yan ZQ.
Innate immune receptor NOD2 promotes vascular inflammation and formation of lipid-rich necrotic cores in hypercholesterolemic mice. Eur J Immunol. 2014 Oct;44(10):3081-92.

6: Assinger A, Wang Y, Butler LM, Hansson GK, Yan ZQ, Söderberg-Nauclér C, Ketelhuth DF. Apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) triggers platelet activation and boosts
platelet-leukocyte proinflammatory responses. Thromb Haemost. 2014 Aug;112(2):332-4129

7: Tsiantoulas D, Sage AP, Mallat Z, Binder CJ. Targeting B cells in atherosclerosis: closing the gap from bench to bedside. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):296-302.

8: Gonen A, Hansen LF, Turner WW, Montano EN, Que X, Rafia A, Chou MY, Wiesner P, Tsiantoulas D, Corr M, VanNieuwenhze MS, Tsimikas S, Binder CJ, Witztum JL, Hartvigsen K. Atheroprotective
immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implica

Top